NEW YORK, April 6 Reportlinker.com announces that a new market research report is available in its catalogue:
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
Advertisement
http://www.reportlinker.com/p0186163/Pipeline-Insight-Gastrointestinal-Cancer-Overview---Metastatic-gastrointestinal-cancers-represent-a-significant-commercial-opportunity-due-to-a-lack-of-approved-drugs.html
Advertisement
Introduction
The five tumor types covered in this report are set to account for nearly 898,000 new patients in 2010. Collectively, the 18 drugs in Phase III development for the gastrointestinal cancers are forecast to achieve $5,404m in sales by 2019. Not all unmet needs will be fulfilled, therefore significant commercial opportunities exist for drug developers seeking to enter the market.
Scope
*Examination of the gastrointestinal cancers pipeline with in-depth clinical and commercial profiles of Phase III candidates
*Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions
*Segmentation and analysis of the current gastrointestinal cancers pipeline by developmental phase, drug class and company
*Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Highlights
There are 166 drugs in clinical development for the gastrointestinal cancers. Molecular targeted therapies are the predominant therapy class in the pipeline, accounting for 67%. Cytotoxic therapies account for 2% of the pipeline, while immunotherapies account for 15% and gene therapies for 16%.
Colorectal cancer is one of the 'big four' tumor types and has traditionally been a popular R&D target due to its high patient and commercial potential. Following the success of Avastin, drug developers are trying to emulate this, with all three late-phase pipeline products for colorectal cancer targeting angiogenesis.
Pancreatic cancer suffers from high levels of unmet need due to poor prognosis and a resistant nature, resulting in a high rate of Phase III failure. High unmet needs are likely to equate to high commercial reward, which has been noticed by drug developers, making pancreatic cancer the second most popular R&D target after colorectal cancer.
Reasons to Purchase
*Identify key drugs and companies within the gastrointestinal cancers pipeline based on sales forecasts to 2019 and Datamonitor drug assessment
*Characterize unmet need and poorly served patient groups within gastrointestinal cancer and assess the potential for pipeline products to fulfill them
*Assess the shifting gastrointestinal cancer market dynamic and how future treatment will incorporate pipeline products
Overview 1
Catalyst 1
Summary 1
ABOUT DATAMONITOR HEALTHCARE 2
About the Oncology pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
Datamonitor insight into the gastrointestinal cancers market 3
Contributing experts 5
Related reports 5
Upcoming related reports 5
TABLE OF CONTENTS 6
1. Pipeline Overview and Dynamics 7
Key findings 7
Pipeline overview 7
Pipeline summary 7
Molecular targeted therapies-either novel agents or marketed products undergoing indication expansion-form the bulk of the current late-phase gastrointestinal cancers pipeline 7
Pancreatic cancer has emerged as a popular R&D target due to a significant level of unmet need which could result in high commercial reward 9
Comparative forecasts 10
Key companies involved in the gastrointestinal cancers pipeline 11
Amgen 11
Eli Lilly 12
Roche 13
Key R&D company strategies 15
The metastatic gastrointestinal cancer population holds the most commercial potential, with the highest levels of unmet need in the second-line setting for some tumor types 15
The inclusion of molecular targeted therapies into treatment of gastrointestinal cancers appears to be the way forward 15
2. R&D Approach 16
Key findings 16
Clinical trial design in gastrointestinal cancers 16
Patient selection 16
Increasingly significant in the era of targeted treatment 16
Clinical trial duration 17
Sufficient follow-up is necessary to establish true clinical benefit 17
The advent of novel therapies 17
Diversity of targeted therapies will require an evolution in clinical trial design 17
Clinical trial endpoints in gastrointestinal cancers 18
Most oncology clinical trials designate multiple endpoints 18
Survival 18
Quality of life 18
Tumor response rates 18
Toxicity 19
Time to tumor progression 19
3. Colorectal Cancer 20
Key findings 20
Disease overview 20
Definition 20
Colorectal cancer is the third most common tumor type and cause of cancer-related death in both men and women 20
Patient segmentation 21
The American Joint Committee on Cancer TNM classification system has replaced the older Dukes staging system 21
Epidemiology 21
Seven major markets 21
Rest of the world 23
Current treatment options 24
Current comparator therapy 27
Eloxatin (oxaliplatin; Sanofi-Aventis) 27
Unmet need in colorectal cancer 27
Better screening approaches needed to decrease mortality rates 28
More effective therapies are needed in both early-stage and advanced disease 28
Biomarkers and the selection of patients may help improve outcomes 29
Target product profile versus current level of attainment 30
Pipeline analysis and forecasts 31
Pipeline summary 31
Comparative forecasts 33
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) 35
Drug overview 35
Drug profile 35
Key historical events 36
Clinical trial data 37
Phase II results show aflibercept to confer better antitumor activity in patients previously treated with Avastin 38
SWOT analysis 38
Datamonitor drug assessment scorecard for aflibercept 39
Clinical and commercial attractiveness 40
Aflibercept's primary development in second-line colorectal cancer means direct competition with Avastin in the first-line setting can be avoided... 40
...although several factors may hamper aflibercept's uptake in the second-line setting 41
Aflibercept still needs to differentiate itself from other angiogenesis inhibitors in development for colorectal cancer 41
Presence in colorectal cancer will aid commercialization of aflibercept 41
Satisfaction of unmet needs 41
Forecasts to 2019 42
Brivanib (BMS-582664; Bristol-Myers Squibb) 43
Drug overview 43
Drug profile 43
Key historical events 44
Clinical trial data 45
Phase I/II results show brivanib to confer better clinical benefit in patients with wild-type KRAS tumors 45
SWOT analysis 46
Datamonitor drug assessment scorecard for brivanib 47
Clinical and commercial attractiveness 47
Better clinical benefit in wild-type KRAS tumors could boost brivanib's apparent efficacy in second-line colorectal cancer 47
Economic evaluation is an encouraging inclusion as part of the Phase III trial endpoints 48
Clinical efficacy of brivanib could be enhanced if Phase III development was alongside chemotherapy... 48
...as could eventual uptake in the second-line colorectal cancer setting 49
Bristol-Myers Squibb offers ideal credentials to ensure brivanib's potential in colorectal cancer is maximized 49
Satisfaction of unmet needs 49
Forecasts to 2019 50
Recentin (cediranib; AstraZeneca) 51
Drug overview 51
Drug profile 51
Key historical events 52
Clinical trial data 53
Top-line results from the Phase III HORIZON III study failed to show any benefit of Recentin over Avastin in combination with first-line chemotherapy 54
Phase II results show Avastin to confer greater progression-free survival alongside standard second-line chemotherapy than Recentin 54
SWOT analysis 55
Datamonitor drug assessment scorecard for Recentin 55
Clinical and commercial attractiveness 56
Phase III HORIZON III results mean Recentin will find it difficult to compete in the first-line setting... 56
...while the ongoing Phase III HORIZON II study is high-risk 57
Avastin's mode of action and formulation may be more effective than Recentin's 57
Targeting the Japanese market? 57
AstraZeneca's strength in the oncology market will be key in Recentin's success 58
Satisfaction of unmet needs 58
Forecasts to 2019 59
4. Esophageal Cancer 60
Key findings 60
Disease overview 60
Definition 60
Esophageal cancer is a major source of cancer-related death 60
Patient segmentation 61
Esophageal cancer has been pathologically staged since 2002 61
Epidemiology 62
Seven major markets 62
Rest of the world 64
Current treatment options 64
Current comparator therapy 66
Xeloda (capecitabine; Roche) 66
Unmet need in esophageal cancer 66
Earlier diagnosis could improve prognosis of esophageal cancer 67
New and more effective systemic therapies for advanced disease are required 68
More effective neoadjuvant and/or adjuvant therapy to reduce relapse rates 68
More large-scale, randomized clinical trials are necessary to define optimal treatment strategies 68
Target product profile versus current level of attainment 69
Pipeline analysis and forecasts 70
Pipeline summary 70
Comparative forecasts 72
Tykerb (lapatinib; GlaxoSmithKline) 73
Drug overview 73
Drug profile 73
Key historical events 74
Clinical trial data 75
One Phase II trial has shown minimal activity in second-line metastatic esophageal cancer, and two Phase II studies have been terminated to date 76
SWOT analysis 76
Datamonitor drug assessment scorecard for Tykerb 77
Clinical and commercial attractiveness 78
Minimal clinical data have been reported for Tykerb in esophageal cancer, making it difficult to judge its clinical attractiveness 78
EGFR inhibition is a popular strategy for gastrointestinal tumors, but experience in esophageal cancer has been dubious so far 79
HER-2 inhibition is a rarer strategy, although has proven successful in gastric cancer 79
Concerns exist over Tykerb's association with hepatotoxicity 79
Tykerb's oral formulation may prove problematic... 80
...however, it could become the first approved therapy for esophageal cancer 80
Satisfaction of unmet needs 80
Forecasts to 2019 81
5. Gastric Cancer 82
Key findings 82
Disease overview 82
Definition 82
Gastric cancer is the second most common tumor type on a global scale 82
Patient segmentation 83
A more detailed Japanese staging system exists for gastric cancer, but is not used in the US or Europe 83
Epidemiology 84
Seven major markets 84
Rest of the world 87
Current treatment options 88
Current comparator therapy 90
Taxotere (docetaxel; Sanofi-Aventis) 90
Unmet need in gastric cancer 91
Lack of effective systemic therapy 92
Poorly defined standard treatment regimens 92
Poor control of distant metastases 93
Complete lack of second-line options 93
Target product profile versus current level of attainment 93
Pipeline analysis and forecasts 94
Pipeline summary 94
Comparative forecasts 96
Herceptin (trastuzumab; Genentech/Roche/Chugai) 99
Drug overview 99
Drug profile 99
Key historical events 100
Clinical trial data 101
Phase III ToGA study shows the addition of Herceptin to first-line chemotherapy to result in a 2.7 month survival benefit in HER-2-positive metastatic gastric cancer 102
SWOT analysis 103
Datamonitor drug assessment scorecard for Herceptin 103
Clinical and commercial attractiveness 104
Herceptin is the first molecular targeted therapy to gain approval for gastric cancer 104
Targeting HER-2-positive patients specifically is in line with the trend for more personalized therapy... 104
...however, restricts Herceptin's commercial potential in gastric cancer 105
Tykerb could pose a competitive threat to Herceptin 105
Concerns exist over Herceptin's association with cardiotoxicity 105
Roche's leading position in the oncology market will almost certainly lead to success 106
Satisfaction of unmet needs 106
Forecasts to 2019 106
Avastin (bevacizumab; Genentech/Roche/Chugai) 107
Drug overview 107
Drug profile 107
Key historical events 108
Clinical trial data 110
The Phase III AVAGAST study failed to meet its primary endpoint of improving overall survival in the first-line metastatic gastric cancer setting 110
Several Phase II studies have shown encouraging survival results associated with Avastin, however, the risk of gastrointestinal perforations and bleeding remains a major concern 110
SWOT analysis 111
Datamonitor drug assessment scorecard for Avastin 112
Clinical and commercial attractiveness 113
Failure of the Phase III AVAGAST study to meet its primary endpoints in first-line metastatic gastric cancer is a setback... 113
...although Avastin could still have a role in resectable gastric cancer 114
Roche's leading position in the oncology market will almost certainly result in success 114
Increasingly cost-conservative healthcare systems could restrict potential uptake of Avastin 114
Satisfaction of unmet needs 115
Forecasts to 2019 115
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) 116
Drug overview 116
Drug profile 116
Key historical events 117
Clinical trial data 118
Several Phase II studies have shown encouraging survival results associated with Erbitux, with a potential tumor response correlation linked to incidence of acneiform rash 119
SWOT analysis 120
Datamonitor drug assessment scorecard for Erbitux 121
Clinical and commercial attractiveness 122
Phase II data show a comparable response rate to the current first-line standard, but the Phase III EXPAND trial will need to demonstrate superior overall survival 122
Erbitux's cost may hinder its uptake in certain markets... 122
...although if use is targeted to specific patient subtypes, then the issue of cost may be overcome 123
Satisfaction of unmet needs 123
Forecasts to 2019 124
Afinitor (everolimus; Novartis) 125
Drug overview 125
Drug profile 125
Key historical events 126
Clinical trial data 127
Phase II results showed 0% overall response rate, but a very encouraging median overall survival of 10.1 months in heavily pretreated metastatic gastric cancer patients 128
SWOT analysis 128
Datamonitor drug assessment scorecard for Afinitor 129
Clinical and commercial attractiveness 130
If Phase III trial replicates Phase II survival, then Afinitor could become the standard of care in second-line metastatic gastric cancer 130
A relatively high rate of treatment discontinuation due to adverse events was seen in the Phase II study 130
Afinitor is set to be the first agent to reach the market for second-line metastatic gastric cancer 131
Afinitor shows applicability for use across the wider gastric cancer population 131
Design of the Phase III GRANITE-1 study may unnecessarily come under fire 131
Novartis's experience in the oncology market will prove crucial in ensuring Afinitor's success in gastric cancer 131
Satisfaction of unmet needs 131
Forecasts to 2019 132
Tykerb (lapatinib; GlaxoSmithKline) 133
Drug overview 133
Drug profile 133
Key historical events 134
Clinical trial data 135
Phase II results have shown minimal activity in first-line metastatic gastric cancer and failure to meet its primary endpoint of overall response rate 136
SWOT analysis 136
Datamonitor drug assessment scorecard for Tykerb 137
Clinical and commercial attractiveness 138
Minimal clinical data have been reported for Tykerb in gastric cancer, making it difficult to judge its clinical attractiveness 138
Dual inhibition of EGFR and HER-2 is a relatively new strategy in treatment of gastric cancer 139
Concerns exist over Tykerb's association with hepatotoxicity 139
Tykerb could provide strong competition to Herceptin in HER-2-positive gastric cancer 139
Satisfaction of unmet needs 139
Forecasts to 2019 140
Ramucirumab (IMC-1121B; Eli Lilly) 141
Drug overview 141
Drug profile 141
Key historical events 142
Clinical trial data 143
Only Phase I results in solid tumors have been made available to date 143
SWOT analysis 144
Datamonitor drug assessment scorecard for ramucirumab 144
Clinical and commercial attractiveness 145
A lack of clinical trial data makes it difficult to judge ramucirumab's potential in gastric cancer 145
Ramucirumab will lose out to Afinitor in terms of first-to-market advantage for second-line gastric cancer 145
The failure of Avastin in the first-line setting may work in ramucirumab's favor 146
Eli Lilly's experience in the oncology market will prove crucial in ensuring ramucirumab's success in gastric cancer 146
Satisfaction of unmet needs 146
Forecasts to 2019 147
6. Hepatocellular Carcinoma 149
Key findings 149
Disease overview 149
Definition 149
Hepatitis is a known risk factor for hepatocellular carcinoma 149
Patient segmentation 150
Several staging systems exist for hepatocellular carcinoma 150
Epidemiology 151
Seven major markets 151
Rest of the world 152
Current treatment options 153
Current comparator therapy 155
Nexavar (sorafenib; Onyx Pharmaceuticals/Bayer Schering) 155
Unmet need in hepatocellular carcinoma 155
Better systemic therapy is required in all lines of treatment 156
Clinical trials are currently poorly designed 157
Target product profile versus current level of attainment 157
Pipeline analysis and forecasts 158
Pipeline summary 158
Comparative forecasts 160
Brivanib (BMS-582664; Bristol-Myers Squibb) 163
Drug overview 163
Drug profile 163
Key historical events 164
Clinical trial data 165
Phase II results show brivanib to confer activity in both the first- and second-line treatment settings for advanced hepatocellular carcinoma 165
SWOT analysis 166
Datamonitor drug assessment scorecard for brivanib 167
Clinical and commercial attractiveness 168
Competing with Nexavar in the first-line setting may be difficult unless brivanib demonstrates significant superiority... 168
...therefore it is commercially astute of Bristol-Myers Squibb to also target alternative treatment settings 169
Development as an adjuvant to first-line trans-arterial chemo-embolization could also enhance uptake of brivanib 169
Bristol-Myers Squibb is well placed to ensure brivanib's potential in hepatocellular carcinoma is maximized 169
Satisfaction of unmet needs 169
Forecasts to 2019 170
Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche) 171
Drug overview 171
Drug profile 171
Key historical events 172
Clinical trial data 173
Phase II results show Tarceva to confer antitumor activity in advanced hepatocellular carcinoma both as a monotherapy, in combination with chemotherapy and in combination with other molecular targeted therapies 174
SWOT analysis 174
Datamonitor drug assessment scorecard for Tarceva 175
Clinical and commercial attractiveness 176
Tarceva in combination with angiogenesis inhibition has resulted in very encouraging survival results... 176
...therefore Phase III development in combination with Nexavar should in theory result in enhanced efficacy 176
The overall cost of a combination of Nexavar and Tarceva could be prohibitively expensive in some markets 177
Roche's leading position in the oncology market will almost certainly result in success 177
Satisfaction of unmet needs 177
Forecasts to 2019 178
Afinitor (everolimus; Novartis) 179
Drug overview 179
Drug profile 179
Key historical events 180
Clinical trial data 181
Phase I data suggest that Afinitor is capable of stabilizing progression of hepatocellular carcinoma 182
SWOT analysis 182
Datamonitor drug assessment scorecard for Afinitor 183
Clinical and commercial attractiveness 183
Afinitor's potential is difficult to judge in hepatocellular carcinoma owing to lack of reported data 183
Afinitor is likely to lose out on first-to-market advantage in second-line gastric cancer... 184
...although its mechanism of action could differentiate it from the competition 184
Novartis's experience in the oncology market will prove crucial to ensuring Afinitor's success in hepatocellular carcinoma 184
Satisfaction of unmet needs 184
Forecasts to 2019 185
Linifanib (ABT-869; Abbott) 186
Drug overview 186
Drug profile 186
Key historical events 187
Clinical trial data 188
Phase II results show linifanib to confer clinical benefit in both the first- and second-line treatment settings for advanced hepatocellular carcinoma 188
SWOT analysis 189
Datamonitor drug assessment scorecard for linifanib 190
Clinical and commercial attractiveness 191
By excluding second-line patients from the ongoing Phase III trial, linifanib could show equivalent or superior survival results to Nexavar 191
Other pipeline agents pose a significant threat to linifanib... 192
...therefore Abbott could also target alternative treatment settings or patient subgroups within hepatocellular carcinoma to differentiate linifanib 192
To maximize linifanib's commercial potential, Abbott would be astute in taking on board a marketing partner 192
Satisfaction of unmet needs 192
Forecasts to 2019 193
ThermoDox (liposomal doxorubicin; Celsion/Yakult Honsha) 194
Drug overview 194
Drug profile 194
Key historical events 195
Clinical trial data 196
Phase I results show a favorable overall response rate and low local recurrence rate for ThermoDox and radiofrequency ablation in hepatocellular carcinoma and cancer metastatic to the liver 196
SWOT analysis 197
Datamonitor drug assessment scorecard for ThermoDox 197
Clinical and commercial attractiveness 198
Phase I results are insufficient to judge ThermoDox's commercial potential 198
Most hepatocellular carcinoma patients present with disease that is too advanced for radiofrequency ablation 199
In order to optimize ThermoDox's commercial potential, Celsion should seek a partner experienced in the oncology market 199
Satisfaction of unmet needs 199
Forecasts to 2019 200
Sutent (sunitinib; Pfizer) 200
Drug overview 200
Drug profile 201
Key historical events 201
Clinical trial data 202
Phase II studies show evidence of some antitumor activity, although toxicity and fatalities associated with Sutent are a concern 203
SWOT analysis 204
Datamonitor drug assessment scorecard for Sutent 205
Clinical and commercial attractiveness 205
Sutent will have to show significantly superior survival benefits in order to effectively compete with Nexavar in the advanced hepatocellular carcinoma population and overcome negative Phase II results 205
Other late-phase pipeline agents also pose a competitive threat to Sutent 206
Altering Sutent's target patient population in hepatocellular carcinoma could be the key to commercial success 206
Pfizer's growing position in the oncology market will assist in Sutent's potential success 206
Satisfaction of unmet needs 206
Forecasts to 2019 207
7. Pancreatic Cancer 209
Key findings 209
Disease overview 209
Definition 209
Pancreatic cancer represents a major health issue in the developed world 209
Patient segmentation 210
The TNM staging system does not take resectability of a tumor into account, therefore an alternative clinical staging system is often used 210
Epidemiology 210
Seven major markets 210
Rest of the world 212
Current treatment options 213
Current comparator therapy 215
Gemzar (gemcitabine; Eli Lilly) 215
Unmet need in pancreatic cancer 217
Pancreatic cancer is associated with exceptionally poor survival rates across all stages of disease 217
Earlier rates of diagnosis are desperately needed in order to boost survival 218
A lack of effective systemic therapies exists, therefore a higher level of R&D interest is needed 219
An effective neoadjuvant or adjuvant regimen is required to prevent high rates of recurrence after surgery for early-stage disease 219
More options for the few patients who receive second-line treatment are needed 219
Target product profile versus current level of attainment 220
Pipeline analysis and forecasts 220
Pipeline summary 220
Comparative forecasts 222
Abraxane (albumin-bound paclitaxel; Abraxis Bioscience/Taiho) 224
Drug overview 225
Drug profile 225
Key historical events 226
Clinical trial data 227
Phase II results show Abraxane monotherapy to confer an encouraging median overall survival in the second-line metastatic pancreatic cancer setting 228
Phase I/II results show the addition of Abraxane to first-line Gemzar to boost median overall survival by several months over Gemzar monotherapy 229
SWOT analysis 230
Datamonitor drug assessment scorecard for Abraxane 230
Clinical and commercial attractiveness 231
A combination of encouraging clinical data and key opinion leader enthusiasm mean Abraxane is currently the most promising late-phase pipeline candidate for pancreatic cancer 231
Identification of a potential biomarker could further increase apparent efficacy of Abraxane in pancreatic cancer 232
The widespread availability of generic standard paclitaxel may hamper uptake of Abraxane... 232
...however, Abraxane's efficacy in pancreatic cancer arises in part due to its albumin-bound formulation 232
The taxanes are not typically used to treat pancreatic cancer... 232
Abraxis Bioscience's experience in breast cancer will prove useful if Abraxane is approved for pancreatic cancer 233
Satisfaction of unmet needs 233
Forecasts to 2019 233
TNFerade (golnerminogene; GenVec) 234
Drug overview 234
Drug profile 234
Key historical events 235
Clinical trial data 236
Interim data from the PACT study show a 25% reduction in the risk of death when TNFerade is added to standard first-line therapy 237
SWOT analysis 237
Datamonitor drug assessment scorecard for TNFerade 238
Clinical and commercial attractiveness 239
Unmet needs in pancreatic cancer are so high, that if final PACT results are positive, TNFerade will be enthusiastically received 239
No gene therapies are approved for cancer in the seven major markets 240
Intratumoral administration into a pancreatic tumor may prove problematic 240
GenVec may struggle to achieve commercial success for TNFerade without a more experienced oncology player 240
Satisfaction of unmet needs 240
Forecasts to 2019 241
Masitinib (AB-1010; AB Science) 242
Drug overview 242
Drug profile 242
Key historical events 243
Clinical trial data 244
Phase II trial shows a first-line combination of Gemzar and masitinib to confer similar efficacy to Gemzar monotherapy and other Gemzar-based combinations 244
SWOT analysis 245
Datamonitor drug assessment scorecard for masitinib 246
Clinical and commercial attractiveness 247
If Phase II results can be replicated in the ongoing Phase III study, then approval will be likely 247
Masitinib should in theory confer greater efficacy alongside Gemzar than Tarceva due to inhibition of multiple pathways 248
AB Science will need to price masitinib competitively in order to enhance its uptake 248
In order to optimize masitinib's commercial potential, AB Science should seek a partner experienced in the human oncology market 248
Satisfaction of unmet needs 248
Forecasts to 2019 249
Tertomotide (GV-1001; Pharmexa/Kael-GemVax) 250
Drug overview 250
Drug profile 250
Key historical events 251
Clinical trial data 252
A Phase III trial investigating GV-1001 followed by sequential Gemzar in advanced pancreatic cancer patients has already failed 252
Phase I/II trial data indicate an immune response is correlated with prolonged survival 253
SWOT analysis 254
Datamonitor drug assessment scorecard for GV-1001 255
Clinical and commercial attractiveness 255
Replication of Phase I/II median survival in the ongoing Phase III studies will almost surely guarantee approval 255
PrimoVax Phase III failure highlights the difficulties of sequencing chemotherapy with therapeutic cancer vaccines 256
GV-1001 may struggle to achieve optimal market penetration without a more experienced oncology player 256
A lack of precedent regarding approval of therapeutic cancer vaccines exists 257
Satisfaction of unmet needs 257
Forecasts to 2019 257
Bibliography 259
Journals 259
Websites 269
Datamonitor reports 274
Other 274
APPENDIX 275
Methodology 275
Epidemiology forecasts 275
Product forecasts 275
Datamonitor drug assessment scorecard 276
About Datamonitor 278
About Datamonitor Healthcare 278
About the Disease analysis team 278
Datamonitor consulting 279
Disclaimer
To order this report:
Pharmaceutical Industry: Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker